Brought to you by 
Series C round brings €31mm for InflaRx
24 Aug 2016
Executive Summary
InflaRx GMBH (developing terminal complement inhibitors for serious inflammatory diseases) raised €31mm ($34mm) through its Series C round from new investors including Staidson Hong Kong Investment, international industrial and family investors, and returning backers. The company will use the funds to advance Phase II trials of lead project IFX1, a monoclonal anti-complement C5a inhibitor in development for septic organ dysfunction. InflaRx also has candidates in early development for acute and chronic inflammatory conditions (including those related to autoimmune diseases and T-cell driven inflammation), and is working on complement diagnostic assays to study the mechanics behind complement activation and consumption.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series C round brings €31mm for InflaRx
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice